Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis - Summary - MDSpire

Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis

  • By

  • Mengke Zhao

  • Lianjun Zhao

  • Yueling Yang

  • Fufeng Wang

  • Jiani Yin

  • Xiaoying Wu

  • Yu Ren

  • Xinyu Su

  • Yirong Wu

  • Luqiao Li

  • Rong Huang

  • Kelin Zheng

  • JiaYu Wang

  • Zhengyun Zou

  • January 27, 2026

  • 0 min

Share

Objective:

To correct the author group for the article regarding circulating tumor DNA analysis in melanoma, specifically acknowledging Lianjun Zhao as a co-first author.

Key Findings:
Interpretation:

It is crucial to acknowledge Lianjun Zhao as a co-first author to accurately reflect contributions to the research.

Limitations:
Conclusion:

This correction ensures proper attribution of contributions to the research, which is vital for maintaining academic integrity.

Original Source(s)

Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis

  • by Mengke Zhao, Lianjun Zhao, Yueling Yang, Fufeng Wang, Jiani Yin, Xiaoying Wu, Yu Ren, Xinyu Su, Yirong Wu, Luqiao Li, Rong Huang, Kelin Zheng, JiaYu Wang, Zhengyun Zou

  • January 27, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report